PLI Scheme for Pharmaceuticals: Your Complete NRI Investment Guide

What Is the PLI Scheme for Pharmaceuticals?

The Production Linked Incentive (PLI) Scheme for Pharmaceuticals is a government program approved in 2021 to boost India's domestic manufacturing of critical medicines and pharmaceutical ingredients. The scheme incentivizes companies—including those owned or co-invested by NRIs—to build new manufacturing facilities (greenfield projects) for Active Pharmaceutical Ingredients (APIs), Key Starting Materials (KSMs), Drug Intermediates (DIs), and bulk drugs.

The core idea is simple: the government pays cash incentives based on how much you produce and sell. This encourages investment in areas where India currently depends on imports, making the country self-reliant in essential medicines while reducing dependence on China and other external suppliers.

A separate but complementary PLI Scheme for Bulk Drugs (approved 2020) focuses specifically on building supply chain resilience by promoting domestic production of critical KSMs, DIs, and APIs to reduce over-reliance on any single source country.

The Numbers: How Big Is This Opportunity?

As of December 2025, the PLI Scheme for Pharmaceuticals has achieved remarkable scale:

Overall Pharma PLI Performance:

Total cumulative investments: ₹41,943 crore (far exceeding the initial ₹17,275 crore commitment)
Products manufactured: 1,988 different pharmaceutical products
Cumulative sales: ₹3,35,036 crore
Cumulative exports: ₹2,15,248 crore
Critical APIs/KSMs/DIs produced: 726 items, of which 191 are being manufactured in India for the first time
Approved projects: 55 projects targeting biopharmaceuticals, oncology drugs, and specialty therapies
Domestic value addition: 83.7% (meaning India now sources the vast majority of value in these drug categories from within its own borders)

Bulk Drugs Segment (Most Relevant for New Investors):

Cumulative investments: ₹4,814 crore against committed ₹4,329.95 crore (111% utilization)
Production capacity created: 56,800 metric tonnes per annum for 28 critical APIs, KSMs, and DIs
Employment generated: 4,896 jobs (up from 2,163 in March 2023)
Domestic sales contribution: ₹28,067 crore from critical APIs and KSMs
Import savings achieved: ₹1,362 crore by March 2025 via domestic capacity for 25 items; approximately ₹1,785 crore in total import substitution
Approved projects: 48 initiatives by 32 firms covering 33 APIs/DIs/KSMs

Investment Growth Trajectory:

March 2023: ₹2,374.93 crore
March 2024: ₹3,721.44 crore
March 2025: ₹4,554.25 crore
December 2025: ₹4,814.10 crore

This steady upward trend shows investor confidence and growing opportunity. The scheme demonstrates that NRI capital is actively flowing into Indian pharma manufacturing, with greenfield projects scaling rapidly.

Broader PLI Programme Context (All 14 Sectors): As of September 2025, India's entire PLI programme across 14 sectors has achieved:

Actual investments: Nearly ₹2 lakh crore
Incremental production and sales: Over ₹18.7 lakh crore
Jobs created: More than 12.6 lakh (both direct and indirect)
Cumulative incentives disbursed: ₹23,946 crore across 12 PLI sectors

This broader context shows that pharma is part of a massive government-backed manufacturing push that includes electronics (domestic mobile production jumped from ₹18,000 crore in 2014-15 to ₹5.45 lakh crore in 2024-25), medical devices, telecom equipment, white goods, and auto components.

Government Incentives: How Much Money Can You Earn?

The scheme disburses incentives based on incremental sales—meaning you earn rewards for the additional production and sales you generate beyond a baseline. Incentive rates range from 3-10% of incremental sales, depending on your product category and performance tier. Some product categories (particularly complex generics and biopharmaceuticals) may offer rates up to 20% of incremental sales.

Disbursement Trends:

Pharma PLI (broader category):

FY 2022-23: ₹655.15 crore
FY 2024-25: ₹2,330 crore

Bulk Drugs Segment:

FY 2022-23: ₹5.95 crore
FY 2024-25: ₹21.30 crore

The sharp increase shows the scheme is maturing and more companies are hitting production targets. For NRI investors, this means the incentive pipeline is real and growing. The Pharma PLI disbursement grew roughly 3.5 times between FY23 and FY25, while Bulk Drugs PLI disbursement grew roughly 3.6 times over the same period.

Incentive Eligibility: You qualify for incentives if your project meets minimum investment thresholds and achieves production targets. Thresholds escalate yearly, requiring 5-10% growth in initial years. The scheme covers:

Biopharmaceuticals
Complex generics
Patented drugs nearing patent expiry
Auto-immune and anti-cancer drugs
Critical APIs and KSMs on the priority list
CDMO (Contract Development and Manufacturing Organization) services
Biotech manufacturing
Medical devices
Orphan drugs, repurposed drugs, anti-diabetic drugs, anti-infective drugs, and cardiovascular drugs

How Long Will Incentives Last?

Incentives are available through FY 2026-27, with the scheme operational through 2027-28. If you are planning to invest now (2025-2026), you have roughly 1-2 years to establish your project and start claiming incentives. This compressed timeline makes swift action essential.

New Biopharma SHAKTI Programme: Fresh Opportunity for 2026-27

The Union Budget 2026-27 announced a new Biopharma SHAKTI programme with ₹10,000 crore allocation over 5 years. This complements the existing PLI schemes and targets:

Biosimilars and biologics capacity building
Clinical trials infrastructure
R&D ecosystems for biopharmaceuticals
Support for smaller and mid-cap firms in the biologics space

This fresh initiative signals the government's sustained commitment to pharma manufacturing beyond the current PLI window. NRI investors should monitor this programme for additional investment opportunities, particularly in companies with R&D spend of 5-8% of revenue and strong regulatory compliance records.

NRI Investment Rules: Can You Invest?

Yes. India's Foreign Direct Investment (FDI) policy explicitly allows NRIs to invest in pharmaceutical manufacturing under the 100% automatic FDI route. This means:

No Prior Government Approval Required: You do not need to seek permission from the government before investing in greenfield pharma projects. You can directly set up a facility in APIs, KSMs, bulk drugs, or related manufacturing without FIPB (Foreign Investment Promotion Board) approval, provided you stay within the automatic route limits.

Automatic Route Limits:

Greenfield projects: 100% FDI allowed automatically
Brownfield projects: Up to 74% FDI allowed automatically; beyond 74%, you need government approval from the Department of Pharmaceuticals

Eligible Investment Activities:

Manufacturing of APIs and bulk drugs
Contract Development and Manufacturing Organization (CDMO) services
Biotech manufacturing
Medical devices
Any PLI-eligible pharmaceutical segment

No NRI-Specific Restrictions: The scheme documents do not mention any restrictions on NRI participation. You are treated the same as domestic investors, provided you meet the project eligibility criteria. NRIs benefit from the same incentive rates, tax benefits, and infrastructure support as Indian investors.

NRI Investment Routes: NRIs investing on a repatriation basis through the NRI portfolio investment scheme or direct FDI route follow the same sectoral caps. NRIs investing on a non-repatriation basis through their NRO accounts get treated as domestic investors for most purposes, which can simplify compliance in certain cases.

Minimum Investment Thresholds

Minimum investment requirements vary by product category:

Bulk drugs and APIs: ₹10-100 crore per project, depending on the specific product and capacity target
Complex generics and biopharmaceuticals: Check the official PLI portal for category-specific thresholds

For exact minimums for your chosen product, visit the official PLI portal at plibulkdrugs.ifciltd.com or pharma.gov.in.

Priority Products for 2025-2026

The scheme prioritizes certain critical APIs and KSMs where India has import dependence. Examples include:

Penicillin-G derivatives (antibiotic base)
Meropenem (antibiotic)
Ritonavir (antiviral)
Erythromycin Thiocyanate
Clavulanic Acid
Artesunate
Losartan
Telmisartan
Ciprofloxacin
Paracetamol (large volume)
Other critical APIs on the official priority list

Investing in these priority items increases your chances of approval and incentive eligibility. Check pharma.gov.in for the latest priority list and any corrigenda (corrections) before finalizing your project.

Infrastructure Support: Bulk Drug Parks

The government has established Bulk Drug Parks in three states to support PLI investors:

Andhra Pradesh
Gujarat
Himachal Pradesh

These parks offer plug-and-play infrastructure, subsidized land, and shared utilities, reducing your setup time and capital expenditure. Many NRI-backed projects are leveraging these parks to accelerate time-to-market and lower initial investment barriers.

Tax Implications for NRI Investors

Concessional Corporate Tax Rate: New manufacturing units under the PLI Scheme qualify for a 15% concessional corporate tax rate (valid till March 31, 2024, with extensions possible under government review). This significantly reduces your tax burden compared to the standard 30% rate, improving your after-tax returns.

Good News on PLI Incentives: PLI incentives are non-taxable in certain cases, meaning the cash you receive from the government may not be subject to income tax. However, this depends on the specific structure of your investment and how you claim the incentive. Consult a tax advisor to structure your claim optimally.

MAT (Minimum Alternate Tax): Eligible PLI units do not face MAT credit restrictions, which is favorable for your tax planning. You can carry forward MAT credits and use them to offset future tax liabilities.

100% Depreciation Benefit: Plant and machinery purchased for your PLI project qualifies for 100% depreciation in the first year, accelerating your tax deductions and improving cash flow in early years.

GST Exemptions: Imports of capital goods and raw materials for your PLI project may qualify for GST exemptions, reducing your setup and operational costs.

FEMA Compliance: As an NRI, you must comply with Foreign Exchange Management Act (FEMA) regulations when repatriating profits or dividends back to your home country. The scheme itself does not restrict repatriation, but you must follow standard FEMA procedures through an authorized dealer (AD) bank. Profit repatriation is fully permitted post-tax.

Double Taxation Avoidance Agreement (DTAA): If your home country has a DTAA with India, you may be eligible for withholding tax relief on dividends (typically 5-10% depending on your country). File your tax returns under the applicable DTAA to claim these benefits and reduce your effective tax burden.

Capital Gains Taxation (2026 Updates): Income-tax Rules, 2026 (effective April 1, 2026) clarify capital gains taxation for cross-border investments using Fair Market Value (FMV) formulas. Short-term capital gains (holding period less than 12 months for listed equity) attract 20% tax. Long-term capital gains exceeding ₹1.25 lakh in a financial year on listed equity attract 12.5% tax. Unlisted shares have different holding period thresholds (24 months for LTCG) and tax rates.

Documentation Requirements: You will need PAN (Permanent Account Number), FEMA compliance documentation, and KYC (Know Your Customer) verification through an AD bank to process investments and repatriate returns.

How to Apply: The Process

Official Portal: Submit your application through the official PLI portal: plibulkdrugs.ifciltd.com or pharma.gov.in

Application Steps: 1. Register on the PLI portal with your company details 2. Submit an Expression of Interest (EOI) with financial commitments and project timelines 3. Provide land acquisition details for your greenfield site 4. Comply with environmental and quality norms for your state 5. Await approval and begin project execution

Application Windows: The scheme has had multiple application windows. The Department of Pharmaceuticals extended the PLI Scheme application deadline for KSMs and APIs from June 14 to July 4, 2025, through official Notice No. 31026/16/2020-Policy dated June 16, 2025. Recent extensions have been announced for 2025-2026 in select categories. Monitor the portal and pharma.gov.in for current application deadlines, as windows may close as the FY 2027-28 incentive deadline approaches.

Eligibility Checks:

Your company must not be a prior defaulter on any government scheme
Your project must align with product-specific ceilings and environmental norms
You must commit to achieving production and sales targets
Your project must meet minimum investment thresholds for your product category
Your facility must maintain USFDA compliance and avoid warning letters or import alerts

Performance Monitoring: Once approved, you must submit quarterly production data and annual sales verification. Underachievement against targets may trigger clawback of incentives, so realistic planning is essential.

Export Opportunity: A Major Advantage

One of the strongest reasons for NRIs to invest in this scheme is the export opportunity. As of December 2025:

Cumulative pharma PLI exports: ₹2,15,248 crore
The scheme has driven substantial exports, aiding global supply chains
Export incentives enhance ROI and provide forex earnings

Broader PLI programme export performance (April-October 2025):

Electronic goods exports: Up 41.94%
Pharmaceutical exports: Up 6.46%
Engineering goods exports: Up 5.35%

If you set up a CDMO or bulk drug manufacturing facility, you can serve global pharmaceutical companies, not just the Indian market. This diversifies your revenue and reduces dependence on domestic demand. Many NRI investors are leveraging this to build global supply chain partnerships and earn premium margins on exports. India now supplies over 20% of global generics to more than 200 countries, creating substantial opportunities for export-oriented manufacturers.

Impact on Indian Pharma Stocks and Listed Companies

The PLI Scheme is reshaping India's pharmaceutical sector. If you are an NRI investor in Indian pharma stocks, here is what you should know:

Positive Sector Tailwinds:

Increased domestic API production reduces import costs for Indian pharma companies
Companies investing in PLI-eligible segments gain competitive advantages and margin expansion
Export growth supports revenue expansion for listed pharma manufacturers
Reduced import dependence strengthens India's pharma self-reliance narrative, attracting global capital
Analysts estimate that PLI beneficiary companies could see margin expansion of 200 to 500 basis points during the incentive period, depending on their product mix and execution capability

Companies to Watch: Large Indian pharma companies and specialized API manufacturers are benefiting from PLI investments. As the scheme drives capacity additions, companies with exposure to bulk drugs and APIs are positioned for growth. The 1,988 products under production and 726 APIs/KSMs represent a massive supply chain opportunity for listed players.

Valuation Impact: The scheme supports long-term earnings growth for pharma companies, which can positively influence stock valuations over the next 2-3 years. Investors in pharma ETFs and mutual funds tracking the sector are indirectly benefiting from PLI-driven capacity expansion.

Key Metrics for Stock Selection: When evaluating pharma stocks for PLI exposure, look for:

PLI approval for specific product categories
Committed capital expenditure toward new API or KSM manufacturing lines
Demonstrated incremental sales growth in PLI-eligible segments
USFDA facility compliance with no warning letters or import alerts
Debt-to-Equity ratio below 1 for R&D sustainability
R&D spend of 5-8% of revenue minimum
Promoter holding above 60% with no pledged shares

Investment Routes for NRI Investors

Listed Pharma Stocks and ETFs: NRIs can buy shares of Indian pharma companies listed on BSE and NSE through their Portfolio Investment Scheme (PIS) linked demat and trading accounts. Several pharma companies that benefit directly from PLI incentives are publicly listed, including major API manufacturers and formulation companies expanding into complex generics.

Pharma sector ETFs and mutual funds offer diversified exposure. NRIs from most countries can invest in Indian mutual funds, though NRIs based in the USA and Canada face restrictions from many fund houses due to FATCA compliance requirements. Always verify that your chosen fund house accepts investments from your country of residence.

Direct Investment in PLI Beneficiary Companies: Some PLI beneficiary companies raise capital through private placements, qualified institutional placements (QIPs), or rights issues. NRIs can participate in these if they hold valid PIS accounts and the investment stays within the FDI sectoral cap.

Unlisted and Startup Pharma Investments: India's pharma startup ecosystem has grown significantly. NRIs can invest in unlisted pharma companies through the FDI route (automatic route for greenfield, government route beyond 74% for brownfield). Angel investing and venture capital participation require compliance with FEMA regulations and RBI guidelines.

Direct FDI in Manufacturing Ventures: NRIs can establish or co-invest in greenfield pharma manufacturing projects under the 100% automatic FDI route. This route requires no prior government approval and allows full profit repatriation post-tax.

Tax Implications for NRI Stock Investors

Dividend Income: Dividends from Indian pharma stocks are taxable in India at applicable slab rates for NRIs. TDS at 20% (plus surcharge and cess) applies on dividend payments. NRIs can claim credit for this tax in their country of residence under the applicable Double Taxation Avoidance Agreement (DTAA).

Capital Gains on Listed Pharma Stocks:

Short-term capital gains (holding period less than 12 months): 20% tax
Long-term capital gains (holding period more than 12 months, gains exceeding ₹1.25 lakh): 12.5% tax

Capital Gains on Unlisted Shares: Unlisted shares have different holding period thresholds (24 months for LTCG) and tax rates. LTCG on unlisted shares (held for more than 24 months) attracts 12.5% tax.

DTAA Benefits: Always check the Double Taxation Avoidance Agreement between India and your country of residence to avoid paying tax twice on the same income. File your tax returns under the applicable DTAA to claim withholding tax relief on dividends (typically 5-10% depending on your country).

Synergy for NRI Investors: Direct Investment Plus Stock Exposure

If you are both a direct FDI investor in a PLI project and a holder of Indian pharma stocks, you benefit from multiple angles: 1. Your direct investment earns government incentives and operational profits 2. Your stock holdings benefit from sector-wide margin expansion and export growth 3. Your portfolio captures both the direct manufacturing upside and the broader pharma sector tailwind 4. Diversification across direct FDI and listed equities reduces concentration risk

Key Risks to Watch

Execution Risk: Companies must meet minimum investment and production thresholds to claim PLI incentives. Missing targets means losing incentive payments. Realistic planning and strong project management are essential.

Regulatory Risk: Changes in drug pricing policy (DPCO), export restrictions, or USFDA compliance issues can offset PLI benefits. Monitor regulatory developments closely.

Currency Risk: NRIs face exchange rate fluctuations between the Indian rupee and their home currency. Consider hedging strategies if you are concerned about rupee depreciation.

PLI 2.0 Adjustments: The government is rejigging PLI incentives (from incremental turnover/net sales basis) to address high GPU/AI server costs and other operational challenges. Stay updated on these changes, as they may affect incentive calculations and viability.

Debt Levels: For stock investors, monitor debt-to-equity ratios of PLI beneficiary companies. High leverage can reduce returns even with PLI incentives.

Supporting Government Initiatives

Several complementary government programmes amplify the PLI scheme's impact and deserve attention from NRI investors:

Export Promotion Mission: Approved by the Union Cabinet on November 12, 2025, with a budget of ₹25,060 crore over six years. This initiative addresses structural bottlenecks that exporters face and could benefit companies across multiple PLI sectors.

Bharat Trade Net: Announced in the Union Budget 2025, this platform aims to digitise trade documentation, improve access to export finance, and integrate India's trade ecosystem with global standards. Companies in the logistics and fintech space could benefit.

UK Comprehensive Economic Partnership Agreement: The recently signed CEPA with the United Kingdom lowers trade barriers for Indian pharma exports, creating additional market opportunities for PLI beneficiary companies.

Upcoming Investment Opportunities

iPHEX-2026: The International Pharma Expo (iPHEX-2026) is scheduled for September 7-9, 2026, at Bharat Mandapam, New Delhi. This event showcases APIs, formulations, and bulk drugs and provides networking and investment opportunities for NRI investors interested in direct participation or partnerships.

Practical Steps for NRI Investors

For Stock Market Investors: 1. Open a PIS account with a designated bank if you want to trade pharma stocks on Indian exchanges 2. Check your broker's eligibility to handle NRI accounts, especially if you reside in the USA or Canada 3. Review PLI beneficiary lists published by the Department of Pharmaceuticals to identify companies with approved projects 4. Monitor quarterly results of PLI beneficiary companies for incremental sales data in eligible product categories 5. Consult a tax advisor in both India and your country of residence to optimize DTAA benefits on dividends and capital gains

For Direct FDI Investors: 1. Identify your target product category and check minimum investment thresholds 2. Assess land availability in bulk drug parks or your preferred location 3. Prepare detailed project feasibility reports with production and sales projections 4. Register on the official PLI portal and submit your Expression of Interest 5. Engage with an authorized dealer (AD) bank for FEMA compliance and fund transfers 6. Maintain quarterly production records and annual sales verification for incentive claims 7. Consult with tax advisors on optimal structuring for repatriation and DTAA benefits

The Bigger Picture

India's pharma PLI scheme is part of a broader government strategy to make India a global manufacturing hub under the Atmanirbhar Bharat initiative. The new Biopharma SHAKTI programme signals sustained commitment beyond the current PLI window. For NRI investors, this creates a multi-year investment theme with:

Companies that successfully scale up domestic API production will benefit from both government incentives and reduced raw material costs over time
The combination of favorable FDI policy (100% automatic route for greenfield) and direct financial incentives through PLI makes Indian pharma one of the more accessible and potentially rewarding sectors for NRI investment
Broader PLI momentum across 14 sectors (₹2 lakh crore in investments, 12.6 lakh jobs created) demonstrates the government's sustained commitment to manufacturing
Export growth (pharma exports up 6.46% in April-October 2025) shows global demand for Indian pharma products

Keep an eye on policy renewals, PLI 2.0 adjustments, and the Biopharma SHAKTI programme rollout for emerging opportunities. The window to establish projects and claim benefits is narrowing as the FY 2027-28 deadline approaches, making swift action essential for those serious about participating in this structural opportunity.